Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131921 | 0.89 | PAOX (0.64) | GSRPAOXGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL6940222 | 0.85 | GSR (0.77) | GSRPAOXRNPEPCPB2 | |
| SCHEMBL14640487 | 0.84 | GSR (0.61) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL14117682 | 0.82 | GNAI3 (0.56) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL15184957 | 0.82 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL22807654 | 0.82 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL17029472 | 0.82 | GSR (0.59) | GSRPAOXGNAI3GNAO1GNAI1 | |
| SCHEMBL9840679 | 0.82 | GSR (0.59) | GSRPAOXGNAI3GNAO1GNAI1 | |
| SCHEMBL14154835 | 0.81 | GNAI3 (0.58) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL13815922 | 0.81 | GSR (0.53) | GSRPAOXGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140288024-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20140288024-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | GSR 1742/4885PAOX 1433/4885GNAI3 3855/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | GSR 1742/4885PAOX 1433/4885GNAI3 3855/4885 |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | GSR 2464/4885PAOX 3004/4885GNAI3 3703/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GSR 1249/4885PAOX 1327/4885GNAI3 3158/4885 |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | DDOST, SDCBP, STT3B | GSR 1735/4885PAOX 1103/4885GNAI3 3859/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GSR 1493/4885PAOX 2307/4885GNAI3 2812/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GSR 1493/4885PAOX 2307/4885GNAI3 2812/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | GSR 1572/4885PAOX 952/4885GNAI3 2280/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GSR 1493/4885PAOX 2307/4885GNAI3 2812/4885 |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | GSR 1742/4885PAOX 1433/4885GNAI3 3855/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | GSR 1572/4885PAOX 952/4885GNAI3 2280/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GSR 1249/4885PAOX 1327/4885GNAI3 3158/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GSR 1249/4885PAOX 1327/4885GNAI3 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.